Concepedia

Haleh Saber

HS

15

Publications

1.5K

Citations

12

H-Index

1997

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Haleh Saber is an author at United States Food and Drug Administration specializing in medicine, oncology, and cancer research.

Top concepts

Publications per year

1997–2025

15

Publications

15

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Michael H. Brave, Vicki Goodman, Edvardas Kaminskas et al. · Clinical Cancer Research · 2008 · 239 citations

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 207 citations

, , +12

An FDA oncology analysis of antibody-drug conjugates

Haleh Saber, John K. Leighton · Regulatory Toxicology and Pharmacology · 2015 · 166 citations

, , +6

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro, Karen M. McGinn, Nicole Verdun et al. · Clinical Cancer Research · 2015 · 156 citations

, , +18

Identification and interpretation of complexity in sedimentation velocity boundaries

Borries Demeler, Haleh Saber, Jeffrey C. Hansen · Biophysical Journal · 1997 · 145 citations · Full text

, , +6

Rows per page

1–5 of 15